The progression of relapsing-onset multiple sclerosis (MS) and its associated disability may be slowing, results from a large population-based study suggest. In an evaluation of more than 7000 ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.

Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key integrating concept in the contemporary view of multiple sclerosis (MS). "The ...

In contrast to traditional measures, such as an increase or worsening of lesions or overall brain atrophy, to signal progression of multiple sclerosis (MS), investigators are proposing atrophied ...

Cognitive impairment is more common and severe in older adults with MS than in younger patients, but this is driven by ...

Multiple sclerosis (MS) is a progressive disease of the central nervous system that can cause symptoms throughout the body, including both physical and cognitive symptoms. Obesity in childhood and ...

“Our data add and expand previous observations on silent progression in MS and are consistent with the view of the disease as a single continuum, in which RAW [relapse-associated worsening] and PIRA ...

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new ...

Multiple sclerosis (MS) is a debilitating disease with few treatment options. But in a new clinical trial, scientists have tested a promising new therapy involving injections of stem cells, which ...

Heidi Crayton, MD, and Maria Lopes, MD, discuss the impact of multiple sclerosis on patients, families, and caregivers, differentiate relapsing forms (relapsing-remitting and primary progressive) from ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.